Signal active
Bio
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe's largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Location
London, England, United Kingdom, Europe
Social
Primary Organization
2014
101-250
Biotechnology, Artificial Intelligence (AI), Health Care, Pharmaceutical
Jobs history
3
Deep Longevity
Founder and CEO
2020 - Current
Sequenom
Consultant
2009 - 2011
AMD
Manager
2002 - 2006
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Alex Zhavoronkov is the Founder & Chief Executive Officer at Insilico Medicine, based in Europe. With a background in Biotechnology, Alex Zhavoronkov has a rich history of leadership and innovation. Alex Zhavoronkov studied Ph.D. Physics @ Moscow State University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
2
0
Personal investment
2
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Jun 06, 2022 | Insilico Medicine | Series D - Insilico Medicine | 60.0M |
Aug 10, 2022 | Insilico Medicine | Series D - Insilico Medicine | 35.0M |
Partner investment
0
There is no partner investment available on this profile
Exits
0
There is no exit available on this Profile
Invest in industries